Interní Med. 2015; 17(3): 128-132

Treatment of idiopathic pulmonary fibrosis in the Czech republic in 2015

doc.MUDr.Martina Vašáková, Ph.D.

Sekce IPP ČPFS

Pneumologická klinika 1. LF UK, Thomayerova nemocnice Praha

Idiopathic pulmonary fibrosis (IPF) is a diffuse primarily fibrosing lung disease of unknown origin. Until 2011 IPF was considered untreatable,

i.e. the currently used treatment modalities did not show any effectivity from the point of view of evidence-based medicine. The

introduction of pirfenidone counted for the milestone in the treatment of IPF. In the Czech republic this drug was available from autumn

2011 by means of so called named-patient programme and since 2012 after a registration in EU pirfenidone was available in the Czech

republic via extraordinary reimbursement of imported drug. Since 1st July 2014 is pirfenidone (ESBRIET, Roche) regularly reimbursed

by healthcare insurance funds. Pirfenidone started new era for patients with IPF and for their physicians as well. Aside this drug a new

antifibrotic agent, nintedanib, is emerging on EU market (OFEV, Boehringer-Ingelheim). It is highly probably that in a near future more

drugs influencing mechanisms of fibroproliferation will appear and IPF treatment options will offer a wide scale o phenotype- specific

treatment modialities, combined treatment included. All of us who care for IPF patients look for that with a hope.

Keywords: idiopathic pulmonary fibrosis, treatment, pirfenidone, nintedanib, phenotype, specific treatment

Published: June 1, 2015  Show citation